权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Neuroepigenetic mechanisms of chronic low back pain using histone deacetylases PET imaging

使用组蛋白脱乙酰酶 PET 成像研究慢性腰痛的神经表观遗传机制

基本信息

批准号：
10665805
负责人：
Hsiao-Ying Wey
金额：
$ 64.74万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-07-01 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10665805
关键词：
Absence of pain sensation Address Adult Affect Age Aging Alzheimer&apos s Disease Amygdaloid structure Analgesics Animal Model Animals Area Astronomy Autopsy Basic Science Behavior Binding Blood Brain Brain Diseases Brain region Cells Chromatin Chronic Chronic low back pain Clinical Cognition Complex Control Groups DNA Data Development Disease Drug Targeting Environment Enzymes Epigenetic Process Female Functional disorder Gene Expression Gene Silencing Genes Genetic Code Goals HDAC1 gene HDAC2 gene Healthcare Heroin Hippocampus Histone Acetylation Histone Deacetylase Histone Deacetylase Inhibitor Histone Deacetylation Histones Human Human Volunteers Hydrocodone Image Income Individual Inflammatory Investigation Knowledge Lead Learning Life Experience Long-Term Effects Magnetic Resonance Imaging Maintenance Malignant Neoplasms Measures Mediating Mediator Memory Mental Depression Mental disorders Modeling Morphine Motor Activity Nerve Neurodegenerative Disorders Neuronal Plasticity Neuropathy Opiate Addiction Opioid Outcome Measure Oxycodone Pain Pain management Pathogenesis Patient Selection Patients Phase Physical Function Play Positron-Emission Tomography Prevalence Process Productivity Proteins Quality of life Regulation Research Research Design Rodent Rodent Model Role Schizophrenia Sex Differences Spinal Cord System Thalamic structure Therapeutic Tissue Sample Translating United States Update Validation Ventral Tegmental Area Visualization brain tissue chronic pain chronic pain management chronic pain patient clinical imaging cohort conditioned place preference cost epigenetic drug gene repression imaging agent imaging study improved kinetic model male mental function neural neurodevelopment novel opioid use pain model pain patient pre-clinical prescription opioid promoter radiotracer response small molecule success uptake visual map

项目摘要

Project Summary / Abstract Histone deacetylase (HDAC) enzymes are chromatin-modifying proteins that have emerged as an important lead in understanding CNS dysfunction. To date, HDAC expression has been measured in a small number of postmortem brain tissue samples from healthy and diseased patients affected by brain disorders including opioid addiction (heroin), schizophrenia, depression, Alzheimer’s disease and provides evidence that altered expression of HDACs in cortex and some subcortical regions (such as the ventral tegmental area), may play a central role in the underpinnings of brain disease. Research in animal models supports that HDAC expression is a critical mediator of neural development/plasticity, aging, cognition, learning and memory. Further, synthetic small molecules targeting HDACs have been shown to normalize HDAC expression levels and alleviate disease-related behaviors in animals. These preclinical evidence underscoring the great need to improve understanding of the relationship between HDAC expressions, brain function and disease pathogenesis in the living human brain. We have recently achieved a major research goal by resolving a PET imaging agent, [11C]Martinostat that selectively binds to a subset of HDAC enzymes. Our imaging studies to date, including more than 40 healthy human volunteers, have identified key features that make [11C]Martinostat a rare and promising CNS HDAC probe including robust brain uptake and high specific binding. We are extremely excited to take a large step forward in understanding neural dysregulation in chronic pain patients by visualizing HDAC in the brains. As a first towards this goal, we propose to investigate the distribution and availability of [11C]Martinostat in chronic low back pain patients with and without taking prescription opioids. When comparing to healthy control group, we can attribute changes in [11C]Martinostat binding related to chronic pain. In addition, our study design allow further investigations on the effects of prescription opioids and sex differences on HDACs availability. Our team at the Martinos Center is one of few in the world that can directly translate basic science advancements to knowledge of the human system. Our preliminary data on [11C]Martinostat in humans age 18-79 years strongly supports the feasibility and success of our proposal for clinical imaging in healthy subjects in adulthood. PET/MR imaging in humans with [11C]Martinostat will deliver answers to fundamental questions about chromatin modifying enzymes in the living human brain in a way that has not been possible until now. Importantly, using [11C]Martinostat to understand the alternation of HDAC expression in chronic pain patients will enable validation of an epigenetic drug target, refine patient selection based on HDAC expression, and facilitate proof of mechanism/target engagement in developing novel analgesics.

项目摘要/摘要组蛋白脱乙酰酶(HDAC)是一种染色质修饰蛋白，已成为一种重要的引导人们了解中枢神经系统功能障碍。到目前为止，HDAC的表达已经在一小部分来自健康和受脑部疾病影响的患者的死后脑组织样本，包括阿片成瘾(海洛因)、精神分裂症、抑郁症、阿尔茨海默病，并提供证据表明在大脑皮层和一些皮质下区域(如腹侧被盖区)，HDACs的表达可能起到在脑部疾病的基础上起着核心作用。动物模型研究支持HDAC的表达是神经发育/可塑性、衰老、认知、学习和记忆的重要调节因子。此外，靶向HDAC的合成小分子已被证明可以使HDAC的表达水平正常化，并减轻动物的疾病相关行为。这些临床前证据强调了极有必要提高对HDAC表达、脑功能和疾病之间关系的理解活体人脑的发病机制。我们最近通过分解一种PET显像剂[11C]Martinostat实现了一个主要的研究目标选择性地与HDAC酶的一个子集结合。到目前为止，我们的成像研究包括40多名健康人类志愿者已经确定了使[11C]Martinostat成为罕见且有前途的CNS HDAC的关键特征探针包括强大的脑摄取和高特异性结合。我们非常兴奋地迈出了一大步通过可视化大脑中的HDAC来了解慢性疼痛患者的神经调节障碍。作为一名为了实现这一目标，我们建议研究[11C]马替诺他汀在慢性阻塞性肺疾病患者中的分布和可用性。服用和不服用处方阿片类药物的下腰痛患者。与健康对照组比较，我们可以将[11C]Martinostat结合的变化归因于慢性疼痛。此外，我们的研究设计允许进一步研究处方阿片类药物和性别差异对HDAC可获得性的影响。我们队在马蒂诺斯中心，是世界上少数几个可以直接将基础科学进步转化为对人类系统的了解。我们在18-79岁人群中对[11C]马替诺他汀的初步数据有力地支持了这一可行性和我们建议在成年健康受试者中进行临床影像检查的成功。应用于人类的PET/MR成像 [11C]Martinostat将回答有关生物中染色质修饰酶的基本问题人类大脑的一种方式，这是直到现在才可能实现的。重要的是，使用[11C]Martinostat来理解慢性疼痛患者中HDAC表达的变化将使表观遗传药物靶点的验证成为可能，根据HDAC表达优化患者选择，并促进机制/目标参与的证明开发新型止痛药。